Royalty Pharma (RPRX) Research & Development (2019 - 2026)

Royalty Pharma has reported Research & Development for 8 years, with the latest figure at $39.8 million in Q1 2026.

• Quarterly Research & Development fell 21.19% year-over-year to $39.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $390.8 million (up 651.54% YoY) and the FY2025 annual result came in at $452.0 million, up 22500.0% from the prior year.
• Research & Development declined to $39.8 million in Q1 2026 per RPRX's latest filing, from $50.5 million in the prior quarter.
• Over five years, Research & Development peaked at $250.0 million in Q2 2025 and troughed at $500000.0 in Q1 2023.
• A 5-year average of $39.6 million and a median of $25.5 million in 2022 frame the typical range for Research & Development.
• The sharpest annual moves came in 2023 and 2025: Research & Development tumbled 99.5% in 2023, then jumped 49900.0% in 2025.
• Over 5 years, Research & Development stood at $50.5 million in 2022, then tumbled by 99.01% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then surged by 10000.0% to $50.5 million in 2025, then decreased by 21.19% to $39.8 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $39.8 million, $50.5 million, and $50.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.